The specific charge to the committee follows:


The IOM will form a committee to determine ways to reduce new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. The committee will assess current prevention and control activities and identify priorities for research, policy, and action. The committee will highlight issues that warrant further investigations and opportunities for collaboration between private and public sectors. In conducting its work, the committee might want to consider:


Strategies for preventing new HBV and HCV infections:

  • Improving vaccine coverage among vulnerable populations to reach national transmission elimination goals.

  • Increasing the proportion of persons aware of their chronic infection status.

  • Identifying barriers to the identification, counseling, and testing of persons at risk for chronic hepatitis, and ways they can be reduced and eliminated.

  • Promoting prevention among adolescents and adults who engage in risky behaviors, particularly those known to have screened positive for HCV and HBV infection.

  • Determining optimal ways to identify, develop, and implement prevention programs among at-risk populations.

  • Development of an effective HCV vaccine.

Strategies for reducing morbidity and mortality from chronic HBV and HCV infections:

  • Providing appropriate medical referral, evaluation, and management of chronically infected persons.

  • Assessing health-care utilization and outcomes for persons with chronic infections, and opportunities for prevention and care to reduce healthcare-related costs.

  • Reducing health disparities in morbidity and mortality from viral hepatitis.

  • Improving clinical surveillance of markers of disease progression and stage of hepatocellular carcinoma associated with chronic viral hepatitis and associated cirrhosis.

Assess the type and quality of data needed from state and local viral hepatitis surveillance systems to guide and evaluate prevention services:

  • Assess the role of acute disease surveillance in monitoring new infections, detecting outbreaks, identifying vaccine failures and documenting the elimination of HBV transmission.

  • Assess the role of state and local chronic disease surveillance in describing the burden of morbidity and mortality related to chronic hepatitis B and hepatitis C and related liver cirrhosis and cancer, the extent of



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement